Acadia Pharmaceuticals Inc (ACAD) concluded trading on Thursday at a closing price of $16.93, with 4.69 million shares of worth about $79.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.80% during that period and on May 08, 2025 the price saw a gain of about 14.31%. Currently the company’s common shares owned by public are about 167.33M shares, out of which, 166.03M shares are available for trading.
Stock saw a price change of 16.20% in past 5 days and over the past one month there was a price change of 20.07%. Year-to-date (YTD), ACAD shares are showing a performance of -7.74% which decreased to -0.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.40 but also hit the highest price of $20.68 during that period. The average intraday trading volume for Acadia Pharmaceuticals Inc shares is 1.74 million. The stock is currently trading 14.65% above its 20-day simple moving average (SMA20), while that difference is up 5.09% for SMA50 and it goes to 1.51% higher than SMA200.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) currently have 167.33M outstanding shares and institutions hold larger chunk of about 104.90% of that.
The stock has a current market capitalization of $2.83B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 12.35, while it has posted earnings per share of $1.37 in the same period. Its PEG reads 16.69 and has Quick Ratio of 2.80 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACAD, volatility over the week remained 6.37% while standing at 5.05% over the month.
Stock’s fiscal year EPS is expected to drop by -60.38% while it is estimated to increase by 62.60% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on February 11, 2025 offering a Hold rating for the stock and assigned a target price of $22 to it. Coverage by Guggenheim stated Acadia Pharmaceuticals Inc (ACAD) stock as a Neutral in their note to investors on January 03, 2025, suggesting a price target of $20 for the stock. On October 10, 2024, Raymond James Resumed their recommendations, while on August 07, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $20. Stock get an Outperform rating from BMO Capital Markets on June 27, 2024.
